The G20 Global Pharma Summit Series-Canada is a pivotal platform for discussing innovative healthcare solutions. A key topic of interest is the use of Medical Cannabis and Cannabinoid Therapies.
Medical Cannabis, containing bioactive compounds like THC and CBD, has shown potential in managing chronic pain, epilepsy, and multiple sclerosis. Cannabinoid Therapies, harnessing these compounds, are being explored for their therapeutic potential.
Canada, being one of the first countries to legalize medical cannabis, is at the forefront of this research. The summit provides an opportunity for global leaders to learn from Canada's experience, discuss regulatory frameworks, and explore the potential of these therapies in improving patient outcomes.
As the pharmaceutical industry evolves, the G20 Global Pharma Summit Series-Canada continues to foster dialogue on innovative therapies like medical cannabis and cannabinoids, contributing to the advancement of global healthcare.